European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U. CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ...

The positive CHMP opinion is based on data from the CABINET Phase III trial, which investigated Cabometyx versus placebo in people living with advanced pNETs or epNETs, whose disease had progressed ...

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen ...

GLP-1 medications have emerged as a physician-supervised option for individuals managing obesity or weight-related conditions ...

Zurich, June 19, 2025 (GLOBE NEWSWIRE) -- Superlab Suisse has announced the opening of its fourth Swiss laboratory facility ...

Dr. Ahmed’s approach is rooted in collaboration with community members, local organizations, and city leaders. Rather than ...

NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U.S. market following the establishment of Exo-top Inc. (“ Exo-TOP ”), the Company’s ...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) Approval based on pivotal results showing improvements in sustained disease ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple countries globally. TLX591, TLX252 and ...

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by ...

Ensign has been a dividend-paying company since 2002.